Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Perez-Fidalgo, J.A. (José Alejandro) | - |
dc.creator | Iglesias, M. (Maria) | - |
dc.creator | Bohn, U. (Uriel) | - |
dc.creator | Calvo, E. (E.) | - |
dc.creator | Garcia, Y. (Yolanda) | - |
dc.creator | Guerra-Alia, E. (Eva) | - |
dc.creator | Manso, L. (Luis) | - |
dc.creator | Santaballa, A. (Ana) | - |
dc.creator | González-Martín, A. (Antonio) | - |
dc.date.accessioned | 2022-06-28T10:06:11Z | - |
dc.date.available | 2022-06-28T10:06:11Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Perez-Fidalgo, J.A. (J. Alejandro); Iglesias, M. (Maria); Bohn, U. (Uriel); et al. "GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer". Future Science OA. 5 (2), 2019, FSO370 | es |
dc.identifier.issn | 2056-5623 | - |
dc.identifier.uri | https://hdl.handle.net/10171/63715 | - |
dc.description.abstract | Response to polyadenosine diphosphate ribose polymerase (PARP) inhibitors in platinum-resistant ovarian cancer and in the absence of BRCA mutations is very low. Combining PARP inhibitors with other agents might overcome this lack of activity. Here we describe the rationale and design of GEICO1601-ROLANDO (resistant ovarian cancer treated with olaparib and pegylated liposomal doxorubin; NCT03161132). ROLANDO is a Phase II single-arm multicenter trial in which patients are treated with a combination of olaparib and pegylated liposomal doxorubicin (PLD) in platinum-resistant epithelial ovarian, primary peritoneal, or Fallopian tube cancer regardless of the BRCA mutation status. The primary end point is progression-free survival at 6 months. Other secondary end points are response rate, disease control rate, quality of life and overall survival. Lay abstract: PARP inhibitors as a single agent have shown very modest activity in platinum-resistant ovarian cancer in a BRCA nonselected population. The GEICO1601-ROLANDO trial is a protocol designed with the aim of assessing efficacy and safety of the combination of olaparib and pegylated liposomal doxorubin followed by olaparib maintenance in this setting. | es_ES |
dc.description.sponsorship | This trial received financial support from AstraZeneca. JA Perez-Fidalgo discloses lectures, advisories or traveling support from AstraZeneca, Roche, Pharmamar, Clovis and Pfizer. E Guerra discloses a role as advisory board for AstraZeneca. L Manso discloses lectures, advisories/consultant role and research funding from Tesaro, AstraZeneca, Roche, Novartis and Celgene. A GonzalezMartin discloses lectures, advisories or traveling support from AstraZeneca, Roche, Tesaro, Clovis, Pfizer-Merck and Pharmamar. The rest of the authors have no disclosures to declare. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Future Science Ltd | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Maintenance | es_ES |
dc.subject | Olaparib | es_ES |
dc.subject | Ovarian cancer | es_ES |
dc.subject | Pegylated liposomal doxorubicin | es_ES |
dc.subject | Platinum-resistant | es_ES |
dc.title | GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.description.note | This work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit: http://creativeco mmons.org/licenses/by/4.0/ | es_ES |
dc.identifier.doi | 10.4155/fsoa-2018-0107 | - |
dadun.citation.number | 2 | es_ES |
dadun.citation.publicationName | Future Science OA | es_ES |
dadun.citation.startingPage | FSO370 | es_ES |
dadun.citation.volume | 5 | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.